MedPage Today3d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Daily6h
Tirzepatide taken for weight loss may lead to Colonic Ischemia: Case report
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
BioSpace7h
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...
The National Law Review2d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
Too Old to Operate3d
Lower Risk of Cardiovascular Death with Tirzepatide in Heart Failure
The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...
Investing3d
Hims & Hers shares tumble as FDA resolves obesity drug shortage
The FDA's latest decision could reshape the market dynamics for obesity drugs, as compounded versions were allowed under U.S. regulations during the shortage. Hims & Hers Health's stock movement today ...
Tennessee woman accused of selling fake weight loss drugs as counterfeit concerns grow
The woman was accused of selling counterfeit versions of popular weight loss drugs, including Ozempic and Wegovy. Experts say ...
BioSpace5d
FDA Issues Warning Letters Against GLP-1 Compounders
The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision ...